Multidimensional landscape of non‐alcoholic fatty liver disease‐related disease spectrum uncovered by big omics data: Profiling evidence and new perspectives

Characterized by hepatic lipid accumulation, non‐alcoholic fatty liver disease (NAFLD) is a multifactorial metabolic disorder that could promote the progression of non‐alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). Benefiting from recent advances in omics technologies, such as high‐throughput sequencing, voluminous profiling data in HCC‐integrated molecular science into clinical medicine helped clinicians with rational guidance for treatments. In this review, we conclude the majority of publicly available omics data on the NAFLD‐related disease spectrum and bring up new insights to inspire next‐generation therapeutics against this increasingly prevalent disease spectrum in the post‐genomic era. Development of omics technologies, such as RNA‐seq, metabonomics, lipidomics, ST RNA‐seq, ATAC‐seq, microbiome‐seq, SC RNA‐seq and others, promotes voluminous profiling data in NASH‐related disease into clinical medicine.